Clinical trials · Boston, MA
Cancer clinical trials in Boston
We’re tracking 801 recruiting cancer studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Boston, MassachusettsAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Boston, MassachusettsAges 18 years+ - NCT07198945Enrolling by invitation
6 vs 12 month follow-up after large colon polyp removal
This trial compares whether a follow-up colonoscopy at 6 or 12 months is better for people who have had a large polyp (20-50 mm) removed. It will help doctors understand the best timing for surveillance.
Boston, MassachusettsAges 18 years+ - NCT03535545RecruitingPhase 1
PET-MRI imaging test in lung cancer and lung disease
This Phase 1 study tests a radioactive imaging agent to help doctors see disease activity in the lungs using PET/MRI scans. It includes healthy volunteers and people with lung cancer, idiopathic pulmonary fibrosis, lung transplant–related lung problems, or certain medication-related lung inflammation.
Boston, MassachusettsAges 18–80 - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT07741058Enrolling by invitation
AI-assisted diagnosis accuracy study for pathologists
This study tests whether an AI tool helps pathologists make more accurate diagnoses when looking at tissue samples. It may lead to better and faster diagnoses for patients in the future.
Boston, MassachusettsAges Any age - NCT07426484RecruitingPhase 4
Testing cosibelimab for advanced skin cancer in specific patients
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Boston, MassachusettsAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Boston, MassachusettsAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Boston, MassachusettsAges 18 years+ - NCT05673148RecruitingPhase 3
Ablation treatment plus usual therapy for limited metastatic bowel cancer
This study tests whether adding “total ablation” (carefully destroying all visible small tumors using surgery, heat/cold treatment, and/or targeted radiation) to standard chemotherapy improves outcomes for people with limited spread of colorectal cancer. It may help by aiming to eliminate all known metastatic spots while you continue usual cancer treatment.
Boston, MassachusettsAges 18 years+ - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Boston, MassachusettsAges 18–59 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Boston, MassachusettsAges 18 years+ - NCT05614739RecruitingPhase 1
Study of vepugratinib for cancers with FGFR3 gene changes
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Boston, MassachusettsAges 18 years+ - NCT05674357Recruiting
Training therapists to help people with cancer distress
This trial trains therapists in evidence-based treatments to reduce distress related to cancer and cancer care. You may be able to join if you’re being treated or followed at MGH Cancer Center and your distress level is high.
Boston, MassachusettsAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Boston, MassachusettsAges 18 years+ - NCT05918640RecruitingPhase 1/Phase 2
Lurbinectedin for cancers with specific EWS-related gene fusions
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
Boston, MassachusettsAges 10 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Boston, MassachusettsAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Boston, MassachusettsAges 18 years+ - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Boston, MassachusettsAges 18–100 - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Boston, MassachusettsAges 18 years+ - NCT06980077RecruitingPhase 2
Ivonescimab for advanced thymic carcinoma
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
Boston, MassachusettsAges 18 years+ - NCT05335928RecruitingPhase 3
Abatacept for immune-therapy heart inflammation in hospitalized adults
This Phase 3 trial tests abatacept to treat myocarditis (inflammation of the heart muscle) caused by immune checkpoint cancer medicines. It may help patients recover faster and safely manage this serious side effect while they are in the hospital.
Boston, MassachusettsAges 18 years+ - NCT06807294Recruiting
Tai chi for nerve damage from chemo
This study tests whether tai chi can help cancer survivors with nerve damage from chemotherapy. You will be randomly assigned to take tai chi classes or join a waitlist group, and the study tracks changes in balance, nerve pain, and quality of life.
Boston, MassachusettsAges 18 years+
Hear when a new Cancer trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting cancer studies listed above.
- Dana-Farber Cancer Institute · 12 studies
- Massachusetts General Hospital · 9 studies
- Beth Israel Deaconess Medical Center · 5 studies
- Boston Medical Center · 4 studies
- Rhode Island Hospital · 3 studies
- Brigham and Women's Hospital · 2 studies
- Lahey Hospital and Medical Center · 2 studies
- Lahey Medical Center-Peabody · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Massachusetts.
Common questions
- Are there cancer clinical trials near Boston?
- Yes. We're currently tracking 801 recruiting cancer studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.